Long-term eculizumab treatment contributes to recovery from end-stage renal disease caused by atypical hemolytic uremic syndrome

Yuji Yamada, Ryohei Abe, Yutaka Okano, Yoshitaka Miyakawa

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

We experienced a favorable outcome in an adult case of atypical hemolytic uremic syndrome (aHUS) after long-term eculizumab treatment. A 38-year-old Japanese man with a history of central retinal vein occlusion was admitted to our hospital with progressive dyspnea. He was found to have non-immune hemolytic anemia, thrombocytopenia, and acute renal failure two weeks after an episode of the common cold. Plasma exchange was ineffective; therefore, we initiated eculizumab after we excluded other thrombotic microangiopathies. Although long-term peritoneal dialysis was required, we successfully discontinued dialysis 18 months after the onset of aHUS with eculizumab.

Original languageEnglish
Pages (from-to)1085-1088
Number of pages4
JournalInternal Medicine
Volume56
Issue number9
DOIs
Publication statusPublished - 2017 Jan 1

Fingerprint

Chronic Kidney Failure
Thrombotic Microangiopathies
Retinal Vein
Common Cold
Retinal Vein Occlusion
Plasma Exchange
Hemolytic Anemia
Peritoneal Dialysis
Acute Kidney Injury
Thrombocytopenia
Dyspnea
Dialysis
Therapeutics
eculizumab
Atypical Hemolytic Uremic Syndrome

Keywords

  • Atypical hemolytic uremic syndrome
  • Eculizumab
  • Peritoneal dialysis
  • Thrombotic microangiopathy

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Long-term eculizumab treatment contributes to recovery from end-stage renal disease caused by atypical hemolytic uremic syndrome. / Yamada, Yuji; Abe, Ryohei; Okano, Yutaka; Miyakawa, Yoshitaka.

In: Internal Medicine, Vol. 56, No. 9, 01.01.2017, p. 1085-1088.

Research output: Contribution to journalArticle

@article{5d816cb3795f4cefa3d853f8e18fe606,
title = "Long-term eculizumab treatment contributes to recovery from end-stage renal disease caused by atypical hemolytic uremic syndrome",
abstract = "We experienced a favorable outcome in an adult case of atypical hemolytic uremic syndrome (aHUS) after long-term eculizumab treatment. A 38-year-old Japanese man with a history of central retinal vein occlusion was admitted to our hospital with progressive dyspnea. He was found to have non-immune hemolytic anemia, thrombocytopenia, and acute renal failure two weeks after an episode of the common cold. Plasma exchange was ineffective; therefore, we initiated eculizumab after we excluded other thrombotic microangiopathies. Although long-term peritoneal dialysis was required, we successfully discontinued dialysis 18 months after the onset of aHUS with eculizumab.",
keywords = "Atypical hemolytic uremic syndrome, Eculizumab, Peritoneal dialysis, Thrombotic microangiopathy",
author = "Yuji Yamada and Ryohei Abe and Yutaka Okano and Yoshitaka Miyakawa",
year = "2017",
month = "1",
day = "1",
doi = "10.2169/internalmedicine.56.7862",
language = "English",
volume = "56",
pages = "1085--1088",
journal = "Internal Medicine",
issn = "0918-2918",
publisher = "Japanese Society of Internal Medicine",
number = "9",

}

TY - JOUR

T1 - Long-term eculizumab treatment contributes to recovery from end-stage renal disease caused by atypical hemolytic uremic syndrome

AU - Yamada, Yuji

AU - Abe, Ryohei

AU - Okano, Yutaka

AU - Miyakawa, Yoshitaka

PY - 2017/1/1

Y1 - 2017/1/1

N2 - We experienced a favorable outcome in an adult case of atypical hemolytic uremic syndrome (aHUS) after long-term eculizumab treatment. A 38-year-old Japanese man with a history of central retinal vein occlusion was admitted to our hospital with progressive dyspnea. He was found to have non-immune hemolytic anemia, thrombocytopenia, and acute renal failure two weeks after an episode of the common cold. Plasma exchange was ineffective; therefore, we initiated eculizumab after we excluded other thrombotic microangiopathies. Although long-term peritoneal dialysis was required, we successfully discontinued dialysis 18 months after the onset of aHUS with eculizumab.

AB - We experienced a favorable outcome in an adult case of atypical hemolytic uremic syndrome (aHUS) after long-term eculizumab treatment. A 38-year-old Japanese man with a history of central retinal vein occlusion was admitted to our hospital with progressive dyspnea. He was found to have non-immune hemolytic anemia, thrombocytopenia, and acute renal failure two weeks after an episode of the common cold. Plasma exchange was ineffective; therefore, we initiated eculizumab after we excluded other thrombotic microangiopathies. Although long-term peritoneal dialysis was required, we successfully discontinued dialysis 18 months after the onset of aHUS with eculizumab.

KW - Atypical hemolytic uremic syndrome

KW - Eculizumab

KW - Peritoneal dialysis

KW - Thrombotic microangiopathy

UR - http://www.scopus.com/inward/record.url?scp=85018418000&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018418000&partnerID=8YFLogxK

U2 - 10.2169/internalmedicine.56.7862

DO - 10.2169/internalmedicine.56.7862

M3 - Article

C2 - 28458317

AN - SCOPUS:85018418000

VL - 56

SP - 1085

EP - 1088

JO - Internal Medicine

JF - Internal Medicine

SN - 0918-2918

IS - 9

ER -